Access and Evidence: Implications of the EPO Safety Debate (Part 2)
This article was originally published in RPM Report
Executive Summary
It looks like CMS is making its restrictive coverage policy on Aranesp and Procrit stick. That is a big hit to Amgen and J&J. It is also an important precedent for other manufacturers: CMS is demonstrating that it can deny coverage based on the absence of evidence-even when the therapy is the standard of care.